{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:28:29Z","timestamp":1792700909986,"version":"4.5.0"},"reference-count":94,"publisher":"Elsevier","isbn-type":[{"value":"9780443344831","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009229","name":"American University in Cairo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009229","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.podrm.2024.10.003","type":"book-chapter","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T07:40:28Z","timestamp":1736408428000},"page":"1-41","source":"Crossref","is-referenced-by-count":2,"title":["Sofosbuvir: A comprehensive profile"],"prefix":"10.1016","member":"78","reference":[{"issue":"1","key":"10.1016\/bs.podrm.2024.10.003_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14218\/JCTH.2014.00041","article-title":"Sofosbuvir, a significant paradigm change in HCV treatment.","volume":"3","author":"McQuaid","year":"2015","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/bs.podrm.2024.10.003_bib2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.antiviral.2014.04.008","article-title":"Beyond sofosbuvir: what opportunity exists for a better nucleoside\/nucleotide to treat hepatitis C?","volume":"107","author":"Sofia","year":"2014","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/bs.podrm.2024.10.003_bib3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/clpt.2013.206","article-title":"Novel therapeutic approaches for hepatitis C","volume":"95","author":"Au","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/bs.podrm.2024.10.003_bib4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40265-014-0179-7","article-title":"Sofosbuvir: first global approval","volume":"74","author":"Keating","year":"2014","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/bs.podrm.2024.10.003_bib5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/nyas.12832","article-title":"Development of sofosbuvir for the treatment of hepatitis C virus infection","volume":"1358","author":"Lawitz","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"7","key":"10.1016\/bs.podrm.2024.10.003_bib6","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s11094-018-1878-2","article-title":"Quantification of sofosbuvir in human plasma: RP-HPLC method development and validation","volume":"52","author":"Rathod","year":"2018","journal-title":"Pharm. Chem. J."},{"issue":"1","key":"10.1016\/bs.podrm.2024.10.003_bib7","article-title":"Effect of sofosbuvir on length of hospital stay in moderate COVID-19 cases; a randomized controlled trial","volume":"10","author":"Bozorgmehr","year":"2022","journal-title":"Arch. Academic Emerg. Med."},{"issue":"6","key":"10.1016\/bs.podrm.2024.10.003_bib8","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jhep.2017.01.025","article-title":"Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: a real-life observational study","volume":"66","author":"Zeng","year":"2017","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/bs.podrm.2024.10.003_bib9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.fjps.2017.11.003","article-title":"Development and validation of stability indicating RP-HPLC method for the simultaneous estimation of Sofosbuvir and Ledipasvir in bulk and their combined dosage form","volume":"4","author":"Mastanamma","year":"2018","journal-title":"Future J. Pharm. Sci."},{"issue":"3","key":"10.1016\/bs.podrm.2024.10.003_bib10","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.31788\/RJC.2018.1132010","article-title":"Concurrent estimation of sofosbuvir and velpatasvir in raw and tablets using stability indicating RP-HPLC method","volume":"11","author":"Saroja","year":"2018","journal-title":"Rasayan J. Chem."},{"key":"10.1016\/bs.podrm.2024.10.003_bib11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.20902\/IJCTR.2019.120305","article-title":"Development and validation of UV spectrophotometric method for the estimation of sofosbuvir and ledipasvir in combined pharmaceutical dosage forms","volume":"12","author":"Kishore","year":"2019","journal-title":"Int. J. ChemTech Res."},{"issue":"4","key":"10.1016\/bs.podrm.2024.10.003_bib12","first-page":"721","article-title":"Draft monograph on sofosbuvir (sofosbuvirum)","volume":"33","author":"Organization","year":"2019","journal-title":"WHO Drug. Inf."},{"issue":"6","key":"10.1016\/bs.podrm.2024.10.003_bib13","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1128\/AAC.00054-12","article-title":"Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus","volume":"56","author":"Lam","year":"2012","journal-title":"Antimicrobial Agents Chemotherapy"},{"issue":"4","key":"10.1016\/bs.podrm.2024.10.003_bib14","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1517\/13543784.2013.775246","article-title":"Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection","volume":"22","author":"Herbst","year":"2013","journal-title":"Expert. Opin. Investig. Drugs"},{"issue":"4","key":"10.1016\/bs.podrm.2024.10.003_bib15","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4103\/0976-500X.142464","article-title":"Sofosbuvir: a novel treatment option for chronic hepatitis C infection","volume":"5","author":"Bhatia","year":"2014","journal-title":"J. Pharmacol. Pharmacother."},{"issue":"3","key":"10.1016\/bs.podrm.2024.10.003_bib16","first-page":"355","article-title":"Factors influencing the intracellular concentrations of the sofosbuvir metabolite GS-331007 (in PBMCs) at 30 days of therapy","volume":"15","author":"Cusato","year":"2022","journal-title":"Pharm. (Basel)"},{"issue":"12","key":"10.1016\/bs.podrm.2024.10.003_bib17","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1111\/jphp.12294","article-title":"Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus","volume":"66","author":"Summers","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/bs.podrm.2024.10.003_bib18","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40262-015-0261-7","article-title":"Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir","volume":"54","author":"Kirby","year":"2015","journal-title":"Clin. Pharmacokinet."},{"issue":"7","key":"10.1016\/bs.podrm.2024.10.003_bib19","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40262-015-0261-7","article-title":"Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir","volume":"54","author":"Kirby","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/bs.podrm.2024.10.003_bib20","first-page":"51","article-title":"Synthetic routes to sofosbuvir","author":"Barth","year":"2016","journal-title":"Synth. Heterocycles Contemporary Med. Chem."},{"key":"10.1016\/bs.podrm.2024.10.003_bib21","unstructured":"B.S. Ross, M.J. Sofia, G.R. Pamulapati, S. Rachakonda, H.-R. Zhang, B.-K. Chun, et al., Process for the production of sofosbuvir European Patent Specification EP 2 913 337 B1. 06-09-2019."},{"key":"10.1016\/bs.podrm.2024.10.003_bib22","unstructured":"V.K. Kaushik, R.V. Krishna, V. Srinivas, T. Bhavanisamkar, Process for the preparation of sofosbuvir WO 2015\/097605 A1. 02-07-2015."},{"issue":"20","key":"10.1016\/bs.podrm.2024.10.003_bib23","doi-asserted-by":"crossref","first-page":"8311","DOI":"10.1021\/jo201492m","article-title":"Synthesis of diastereomerically pure nucleotide phosphoramidates","volume":"76","author":"Ross","year":"2011","journal-title":"J. Org. Chem."},{"issue":"3","key":"10.1016\/bs.podrm.2024.10.003_bib24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3390\/cryst10030209","article-title":"Determination and data correlation of solubility of sofosbuvir polymorphs in ethyl acetate + toluene and methyl tert-butyl ether binary solvents at the temperature range from 268.15 to 308.15 K","volume":"10","author":"Ji","year":"2020","journal-title":"Crystals"},{"issue":"3","key":"10.1016\/bs.podrm.2024.10.003_bib25","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1021\/acs.jced.1c00860","article-title":"Research on solubility measurement, solvent effects, preferential solvation, and model correlation of sofosbuvir form A in different pure and binary solvents","volume":"67","author":"Xing","year":"2022","journal-title":"J. Chem. Eng. Data"},{"issue":"2","key":"10.1016\/bs.podrm.2024.10.003_bib26","first-page":"90","article-title":"Novel and facile spectrophotometric techniques for the determination of sofosbuvir and ledipasvir in their tablet dosage form","volume":"7","author":"Abdelfatah","year":"2018","journal-title":"J. Anal. Pharm. Res."},{"issue":"19","key":"10.1016\/bs.podrm.2024.10.003_bib27","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1021\/jm100863x","article-title":"Discovery of a \u03b2-d-2\u2032-deoxy-2\u2032-\u03b1-fluoro-2\u2032-\u03b2-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus","volume":"53","author":"Sofia","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.podrm.2024.10.003_bib28","unstructured":"A.C. Society, Molecule of the week archive, 2018, 30\u20134-2018 [cited 2023 15\u201310]; Available from: https:\/\/www.acs.org\/molecule-of-the-week\/archive\/s\/sofosbuvir.html."},{"key":"10.1016\/bs.podrm.2024.10.003_bib29","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jaap.2016.11.003","article-title":"Study on the thermal decomposition of sofosbuvir","volume":"123","author":"Wang","year":"2017","journal-title":"J. Anal. Appl. Pyrolysis"},{"key":"10.1016\/bs.podrm.2024.10.003_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2019.104437","article-title":"Validated 1H and 19F nuclear magnetic resonance for the quantitative determination of the hepatitis C antiviral drugs sofosbuvir, ledipasvir, and daclatasvir in tablet dosage forms","volume":"152","author":"Nasr","year":"2020","journal-title":"Microchem. J."},{"issue":"1","key":"10.1016\/bs.podrm.2024.10.003_bib31","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5155\/eurjchem.8.1.8-12.1514","article-title":"Validated simultaneous spectrophotometric quantification of a new antiviral combination","volume":"8","author":"Abdel-Gawad","year":"2017","journal-title":"Eur. J. Chem."},{"issue":"3","key":"10.1016\/bs.podrm.2024.10.003_bib32","doi-asserted-by":"crossref","first-page":"375","DOI":"10.5155\/eurjchem.7.3.375-379.1439","article-title":"Simple chromatographic and spectrophotometric determination of sofosbuvir in pure and tablet forms","volume":"7","author":"Abdel-Gawad","year":"2016","journal-title":"Eur. J. Chem."},{"key":"10.1016\/bs.podrm.2024.10.003_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2019.103996","article-title":"Spectrophotometric and robust UPLC methods for simultaneous determination of velpatasvir and sofosbuvir in their tablet","volume":"149","author":"Kamal","year":"2019","journal-title":"Microchem. J."},{"issue":"1","key":"10.1016\/bs.podrm.2024.10.003_bib34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s43094-023-00519-8","article-title":"Simultaneous spectrophotometric determination of recombined sofosbuvir, ledipasvir and paracetamol together as commonly repurposed drugs for COVID-19 treatment","volume":"9","author":"Gamal","year":"2023","journal-title":"Future J. Pharm. Sci."},{"issue":"2","key":"10.1016\/bs.podrm.2024.10.003_bib35","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/22297928.2017.1410441","article-title":"UV-spectrophotometric and stability indicating RP-HPLC methods for the determination of the hepatitis C virus inhibitor sofosbuvir in tablet dosage form","volume":"8","author":"Hassouna","year":"2018","journal-title":"Anal. Chem. Lett."},{"key":"10.1016\/bs.podrm.2024.10.003_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.saa.2021.120623","article-title":"Innovative derivative\/zero ratio spectrophotometric method for simultaneous determination of sofosbuvir and ledipasvir: application to average content and uniformity of dosage units","volume":"267","author":"El-Shorbagy","year":"2022","journal-title":"Spectrochim. Acta Part A: Mol. Biomol. Spectrosc."},{"issue":"1","key":"10.1016\/bs.podrm.2024.10.003_bib37","first-page":"16","article-title":"Different spectral data processing techniques for determination of ledipasvir and sofosbuvir in their pure and dosage forms; a comparative study","volume":"5","author":"Salama","year":"2018","journal-title":"Int. J. Sci."},{"key":"10.1016\/bs.podrm.2024.10.003_bib38","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.saa.2017.04.052","article-title":"Simultaneous determination of the brand new two-drug combination for the treatment of hepatitis C: Sofosbuvir\/ledipasvir using smart spectrophotometric methods manipulating ratio spectra","volume":"183","author":"Eissa","year":"2017","journal-title":"Spectrochim. Acta Part A: Mol. Biomol. Spectrosc."},{"key":"10.1016\/bs.podrm.2024.10.003_bib39","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.saa.2017.07.066","article-title":"A new innovative spectrophotometric method for the simultaneous determination of sofosbuvir and ledipasvir","volume":"188","author":"Mansour","year":"2018","journal-title":"Spectrochim. Acta Part A: Mol. Biomol. Spectrosc."},{"key":"10.1016\/bs.podrm.2024.10.003_bib40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.vibspec.2019.04.002","article-title":"Employ fourier transform infrared spectroscopy spectroscopy for determination of second-generation anti-HCV (sofosbuvir, daclatasvir) drugs: application to uniformity of dosage units","volume":"102","author":"Abdel-Lateef","year":"2019","journal-title":"Vibrational Spectrosc."},{"key":"10.1016\/bs.podrm.2024.10.003_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.saa.2022.121012","article-title":"Application of different spectrophotometric methods for quantitative analysis of direct acting antiviral drugs simeprevir and sofosbuvir","volume":"272","author":"Ramzy","year":"2022","journal-title":"Spectrochim. Acta Part A: Mol. Biomol. Spectrosc."},{"key":"10.1016\/bs.podrm.2024.10.003_bib42","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.saa.2019.01.058","article-title":"Spectrophotometric assessment of the brand new antiviral combination: sofosbuvir and velpatasvir in their pure forms and pharmaceutical formulation","volume":"213","author":"Rezk","year":"2019","journal-title":"Spectrochim. Acta Part A: Mol. Biomol. Spectrosc."},{"issue":"9","key":"10.1016\/bs.podrm.2024.10.003_bib43","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/10826076.2018.1462203","article-title":"Application of different analytical techniques for determination of velpatsvir and sofosbuvir in the pharmaceutical preparation","volume":"41","author":"Attia","year":"2018","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"key":"10.1016\/bs.podrm.2024.10.003_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.saa.2021.119429","article-title":"Improved spectral resolution for the rapid simultaneous spectrophotometric determination of sofosbuvir and daclatasvir as anti hepatitis C virus drugs in pharmaceutical formulation and biological fluid using continuous wavelet and derivative transform","volume":"251","author":"Keyvan","year":"2021","journal-title":"Spectrochim. Acta Part A: Mol. Biomol. Spectrosc."},{"key":"10.1016\/bs.podrm.2024.10.003_bib45","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.saa.2018.07.018","article-title":"Earth-friendly spectrophotometric methods for simultaneous determination of ledipasvir and sofosbuvir: Application to average content and uniformity of dosage unit testing","volume":"205","author":"El-Shorbagy","year":"2018","journal-title":"Spectrochim. Acta Part A: Mol. Biomol. Spectrosc."},{"issue":"2","key":"10.1016\/bs.podrm.2024.10.003_bib46","first-page":"114","article-title":"Validated ultraviolet-spectrometric method for determination of sofosbuvir in tablets formulation","volume":"7","author":"El Hamd","year":"2017","journal-title":"J. Appl. Pharm. Sci."},{"issue":"1","key":"10.1016\/bs.podrm.2024.10.003_bib47","first-page":"74","article-title":"Development and validation of eco-friendly spectroscopic methods for the determination of sofosbuvir using eosin Y as an ion pairing reagent","volume":"42","author":"Manal","year":"2023","journal-title":"Lat. Am. J. Pharm."},{"issue":"4","key":"10.1016\/bs.podrm.2024.10.003_bib48","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.5740\/jaoacint.16-0295","article-title":"Comparative validation of the determination of sofosbuvir in pharmaceuticals by several inexpensive ecofriendly chromatographic, electrophoretic, and spectrophotometric methods","volume":"100","author":"El-Yazbi","year":"2017","journal-title":"J. AOAC Int."},{"issue":"4","key":"10.1016\/bs.podrm.2024.10.003_bib49","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jpha.2017.04.003","article-title":"Potential of RP-UHPLC-DAD-MS for the qualitative and quantitative analysis of sofosbuvir in film coated tablets and profiling degradants","volume":"7","author":"Contreras","year":"2017","journal-title":"J. Pharm. Anal."},{"issue":"01","key":"10.1016\/bs.podrm.2024.10.003_bib50","first-page":"S151","article-title":"New stability indicating ultrafast liquid chromatographic method for the determination of sofosbuvir in tablets","volume":"12","author":"Annapurna","year":"2018","journal-title":"Asian J. Pharmaceutics (AJP)"},{"key":"10.1016\/bs.podrm.2024.10.003_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114254","article-title":"Development of a deep eutectic solvent-based ultrasound-assisted homogenous liquid-liquid microextraction method for simultaneous extraction of daclatasvir and sofosbuvir from urine samples","volume":"204","author":"Jouyban","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"11","key":"10.1016\/bs.podrm.2024.10.003_bib52","doi-asserted-by":"crossref","first-page":"8160","DOI":"10.1016\/j.arabjc.2020.09.048","article-title":"Effective quantification of ravidasvir (an NS5A inhibitor) and sofosbuvir in rat plasma by validated LC-MS\/MS method and its application to pharmacokinetic study","volume":"13","author":"Hefnawy","year":"2020","journal-title":"Arab. J. Chem."},{"key":"10.1016\/bs.podrm.2024.10.003_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104859","article-title":"Sofosbuvir shows a protective effect against vertical transmission of Zika virus and the associated congenital syndrome in rhesus monkeys","volume":"182","author":"Gardinali","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/bs.podrm.2024.10.003_bib54","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jchromb.2018.10.020","article-title":"Rapid bioanalytical LC-MS\/MS method for the simultaneous determination of sofosbuvir and velpatasvir in human plasma-application to a pharmacokinetic study in Egyptian volunteers","volume":"1102","author":"Elkady","year":"2018","journal-title":"J. Chromatogr. B"},{"issue":"6","key":"10.1016\/bs.podrm.2024.10.003_bib55","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1159\/000499161","article-title":"Effect of hemodialysis on efficacy and pharmacokinetics of sofosbuvir coformulated with either daclatasvir or ledipasvir in patients with end-stage renal disease","volume":"49","author":"Lin","year":"2020","journal-title":"Blood Purif."},{"issue":"3","key":"10.1016\/bs.podrm.2024.10.003_bib56","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.pharma.2020.01.007","article-title":"Micellar high performance liquid chromatographic method for separation and validation of two anti-hepatitis C- virus drugs in pure form, human plasma and human urine","volume":"78","author":"Hassan","year":"2020","journal-title":"Ann. Pharm. Fran\u00e7aises"},{"key":"10.1016\/bs.podrm.2024.10.003_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113860","article-title":"Rapid and sensitive UHPLC-DAD method for simultaneous determination of sofosbuvir and ledipasvir in human serum","volume":"195","author":"Majnooni","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/bs.podrm.2024.10.003_bib58","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jchromb.2017.12.018","article-title":"UPLC\u2013MS\/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV\/HCV co-infected patients","volume":"1073","author":"Notari","year":"2018","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/bs.podrm.2024.10.003_bib59","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jchromb.2016.06.004","article-title":"Quantification of sofosbuvir and ledipasvir in human plasma by UPLC\u2013MS\/MS method: application to fasting and fed bioequivalence studies","volume":"1028","author":"Rezk","year":"2016","journal-title":"J. Chromatogr. B"},{"issue":"1","key":"10.1016\/bs.podrm.2024.10.003_bib60","doi-asserted-by":"crossref","first-page":"59","DOI":"10.22270\/ajprd.v8i1.659","article-title":"Quantification of plasma levels of antiviral drug sofosbuvir and its metabolite GS331007 in patients of chronic hepatitis C with chronic kidney disease using UPLC-MS\/MS method","volume":"8","author":"Singhala","year":"2020","journal-title":"Asian J. Pharm. Res. Dev."},{"key":"10.1016\/bs.podrm.2024.10.003_bib61","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6535816","article-title":"Development of a robust UPLC method for simultaneous determination of a novel combination of sofosbuvir and daclatasvir in human plasma: clinical application to therapeutic drug monitoring","volume":"2018","author":"Al-Tannak","year":"2018","journal-title":"Int. J. Anal. Chem."},{"issue":"4","key":"10.1016\/bs.podrm.2024.10.003_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9734\/ajacr\/2019\/v3i430097","article-title":"Validated stability\u2013indicating methods for determination of sofosbuvir by UPLC and HPTLC in pure form and tablet dosage forms","volume":"3","author":"Abdel-Razeq","year":"2019","journal-title":"Asian J. Appl. Chem. Res."},{"issue":"6","key":"10.1016\/bs.podrm.2024.10.003_bib63","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/chromsci\/bmab100","article-title":"HPLC-UV and TLC-densitometry methods for simultaneous determination of sofosbuvir and daclatasvir: application to Darvoni\u00ae tablet","volume":"60","author":"Fayed","year":"2021","journal-title":"J. Chromatographic Sci."},{"key":"10.1016\/bs.podrm.2024.10.003_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2022.108324","article-title":"Eco friendly stability indicating HPTLC method for simultaneous determination of sofosbuvir and ledipasvir in pharmaceutical tablets and HPTLC-MS characterization of their degradation products","volume":"186","author":"El-Waey","year":"2023","journal-title":"Microchem. J."},{"key":"10.1016\/bs.podrm.2024.10.003_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2019.104584","article-title":"Eco-friendly HPTLC method for simultaneous analysis of sofosbuvir and ledipasvir in biological and pharmaceutical samples: stability indicating study","volume":"154","author":"El-Yazbi","year":"2020","journal-title":"Microchem. J."},{"issue":"1","key":"10.1016\/bs.podrm.2024.10.003_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40543-019-0197-x","article-title":"Simultaneous chromatographic analysis of Sofosbuvir\/Ledipasvir in their combined dosage form: an application to green analytical chemistry","volume":"10","author":"Hemdan","year":"2019","journal-title":"J. Anal. Sci. Technol."},{"issue":"2","key":"10.1016\/bs.podrm.2024.10.003_bib67","doi-asserted-by":"crossref","first-page":"129","DOI":"10.25004\/IJPSDR.2020.120206","article-title":"Stability indicating HPTLC method for sofosbuvir and velpatasvir in combination","volume":"12","author":"Damle","year":"2020","journal-title":"Int. J. Pharm. Sci. Drug. Res."},{"issue":"9","key":"10.1016\/bs.podrm.2024.10.003_bib68","first-page":"2241","article-title":"Analytical method and validation for the estimation of sofosbuvir and ledipasvir in raw material and tablet formulation by high performance thin layer chromatographic (HPTLC) method world","volume":"10","author":"Jayaprakash","year":"2021","journal-title":"J. Pharm. Pharm. Sci."},{"issue":"12","key":"10.1016\/bs.podrm.2024.10.003_bib69","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s11094-021-02359-3","article-title":"Development of stability indicating HPLC-UV method for determination of process impurities and degradation products in sofosbuvir and velpatasvir tablets","volume":"54","author":"Zaman","year":"2021","journal-title":"Pharm. Chem. J."},{"key":"10.1016\/bs.podrm.2024.10.003_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2022.108344","article-title":"Green RP-HPLC method for simultaneous determination of sofosbuvir, ledipasvir, velpatasvir antivirals and beyond in their bulk material and co-formulated products","volume":"186","author":"Mohamed","year":"2023","journal-title":"Microchem. J."},{"key":"10.1016\/bs.podrm.2024.10.003_bib71","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.microc.2019.03.039","volume":"147","author":"El-Shorbagy","year":"2019","journal-title":"Microchem. J."},{"issue":"8","key":"10.1016\/bs.podrm.2024.10.003_bib72","first-page":"2249","article-title":"Development and validation of RP-HPLC method for quantitative analysis of sofosbuvir in pure and pharmaceutical formulation","volume":"6","author":"Shaikh","year":"2017","journal-title":"World J. Pharm. Pharm. Sci."},{"issue":"2","key":"10.1016\/bs.podrm.2024.10.003_bib73","first-page":"164","volume":"11","author":"Ali","year":"2018","journal-title":"Development and validation of analytical method for concurrent assesment by RP-HPLC of sofosbuvir and velpatasvir in pharmaceutical dosage form"},{"issue":"2","key":"10.1016\/bs.podrm.2024.10.003_bib74","first-page":"82","article-title":"Development of validated bioanalytical RP-HPLC method for determination of sofosbuvir in human plasma","volume":"10","author":"Satheshkumar","year":"2020","journal-title":"Am. J. Pharm. Res."},{"issue":"1","key":"10.1016\/bs.podrm.2024.10.003_bib75","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s43094-021-00285-5","article-title":"Development and validation of RP HPLC method for the estimation of Sofosbuvir and related impurity in bulk and pharmaceutical dosage form","volume":"7","author":"Ganji","year":"2021","journal-title":"Future J. Pharm. Sci."},{"issue":"6","key":"10.1016\/bs.podrm.2024.10.003_bib76","doi-asserted-by":"crossref","first-page":"59","DOI":"10.53879\/id.56.06.11702","article-title":"Development and validation of RH HPLC method for the estimation of sofosbuvir in bulk tablets and industrial waste","volume":"56","author":"Dhanunjayachary","year":"2019","journal-title":"Water Indian. Drugs"},{"issue":"3","key":"10.1016\/bs.podrm.2024.10.003_bib77","first-page":"1319","article-title":"A new stability indicating RP-HPLC method development and validation of for simultaneous estimation of velpatasvir and sofosbuvir","volume":"10","author":"Kandiboti","year":"2023","journal-title":"Gis Sci. J."},{"key":"10.1016\/bs.podrm.2024.10.003_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2022.113282","article-title":"RP-HPLC method development, validation, and drug repurposing of sofosbuvir pharmaceutical dosage form: a multidimensional study","volume":"212","author":"Mangrio","year":"2022","journal-title":"Environ. Res."},{"issue":"12","key":"10.1016\/bs.podrm.2024.10.003_bib79","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s10337-021-04099-8","article-title":"Forced degradation studies of sofosbuvir with a developed and validated RP-HPLC method as per ICH guidelines","volume":"84","author":"Hamdache","year":"2021","journal-title":"Chromatographia"},{"issue":"20","key":"10.1016\/bs.podrm.2024.10.003_bib80","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.3390\/molecules25204611","article-title":"Validated reversed-phase liquid chromatographic method with gradient elution for simultaneous determination of the antiviral agents: sofosbuvir, ledipasvir, daclatasvir, and simeprevir in their dosage forms","volume":"25","author":"Ezzeldin","year":"2020","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/bs.podrm.2024.10.003_bib81","doi-asserted-by":"crossref","first-page":"143","DOI":"10.22270\/jddt.v10i5.4296","article-title":"New analytical method development and validation for simultaneous estimation of sofosbuvir and velpatasvir in bulk and pharmaceutical dosage form by RP-HPLC method","volume":"10","author":"Hanuman","year":"2020","journal-title":"J. Drug. Deliv. Ther."},{"key":"10.1016\/bs.podrm.2024.10.003_bib82","first-page":"307","article-title":"Stability indicating method development and validation for the simultaneous estimation of ledipasvir and sofosbuvir in bulk drug by using RP-HPLC","author":"Bhavani","year":"2020","journal-title":"World J. Curr. Med. Pharm. Res."},{"issue":"3","key":"10.1016\/bs.podrm.2024.10.003_bib83","doi-asserted-by":"crossref","first-page":"19","DOI":"10.38111\/ijapb.20200603006","article-title":"New RP-HPLC method for simultaneous estimation of sofosbuvir and velpatasvir in combined pharmaceutical dosage forms","volume":"6","author":"Revathi","year":"2020","journal-title":"Int. J. Adv. Pharm. Biotechnol."},{"issue":"6","key":"10.1016\/bs.podrm.2024.10.003_bib84","first-page":"1500","article-title":"Analytical method development & validation for the simultaneous estimation of velpatasvir and sofosbuvir in bulk and its dosage form by RP-HPCL","volume":"9","author":"Krishna","year":"2020","journal-title":"World J. Pharm. Res."},{"key":"10.1016\/bs.podrm.2024.10.003_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2020.105251","article-title":"A green stability-indicating RP-HPLC-UV method using factorial design for determination of ribavirin, sofosbuvir and ledipasvir: application to average content, acid degradation kinetics and in vitro drug interactions study","volume":"158","author":"El-Shorbagy","year":"2020","journal-title":"Microchem. J."},{"issue":"4","key":"10.1016\/bs.podrm.2024.10.003_bib86","first-page":"1835","article-title":"Development and validation of a stability-Indicating RP-HPLC method for simultaneous estimation of sofosbuvir and velpatasvir in fixed dose combination tablets and plasma","volume":"32","author":"Mehmood","year":"2019","journal-title":"Pak. J. Pharm. Sci."},{"issue":"04","key":"10.1016\/bs.podrm.2024.10.003_bib87","doi-asserted-by":"crossref","first-page":"10","DOI":"10.30750\/ijpbr.5.4.3","article-title":"Stability indicating RP-HPLC method development and validation for the simultaneous determination of Sofosbuvir and Velpatasvir in tablet dosage forms","volume":"5","author":"Bandla","year":"2017","journal-title":"Indian. J. Pharm. Biol. Res."},{"issue":"7","key":"10.1016\/bs.podrm.2024.10.003_bib88","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1080\/03639045.2019.1593444","volume":"45","author":"Baker","year":"2019","journal-title":"Drug. Dev. Ind. Pharm."},{"issue":"2","key":"10.1016\/bs.podrm.2024.10.003_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9734\/jpri\/2019\/v26i230135","article-title":"A novel stress indicating RP-HPLC method development and validation for the simultaneous estimation of velpatasvir and sofosbuvir in bulk and its tablet dosage form","volume":"26","author":"Chinababu","year":"2019","journal-title":"J. Pharm. Res. Int."},{"key":"10.1016\/bs.podrm.2024.10.003_bib90","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jchromb.2019.01.024","article-title":"Quantification of second generation direct-acting antivirals daclatasvir, elbasvir, grazoprevir, ledipasvir, simeprevir, sofosbuvir and velpatasvir in human plasma by UPLC-MS\/MS","volume":"1110","author":"van Seyen","year":"2019","journal-title":"J. Chromatogr. B"},{"issue":"9","key":"10.1016\/bs.podrm.2024.10.003_bib91","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.5958\/0974-360X.2018.00762.X","article-title":"A new simple stability-indicating RP-HPLC-PDA method for simultaneous estimation of triplicate mixture of sofosbuvir, velpatasvir and voxilaprevir in tablet dosage form","volume":"11","author":"Balaswami","year":"2018","journal-title":"Res. J. Pharm. Technol."},{"key":"10.1016\/bs.podrm.2024.10.003_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13065-019-0635-2","article-title":"Two novel UPLC methods utilizing two different analytical columns and different detection approaches for the simultaneous analysis of velpatasvir and sofosbuvir: application to their co-formulated tablet","volume":"13","author":"Moustapha","year":"2019","journal-title":"BMC Chem."},{"issue":"3","key":"10.1016\/bs.podrm.2024.10.003_bib93","doi-asserted-by":"crossref","first-page":"35","DOI":"10.22159\/ijpps.2017v9i3.16185","article-title":"Bioanalytical method development and validation for the determination of sofosbuvir from human plasma","volume":"9","author":"Madhavi","year":"2017","journal-title":"Int. J. Pharm. Pharm Sci."},{"issue":"3","key":"10.1016\/bs.podrm.2024.10.003_bib94","first-page":"001","article-title":"Assay and dissolution methods development and validation for simultaneous determination of sofosbuvir and ledipasvir by RP-HPLC method in tablet dosage forms","volume":"1","author":"Hassouna","year":"2017","journal-title":"J. Forensic Sci. Crim. Inves."}],"container-title":["Profiles of Drug Substances, Excipients and Related Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871512524000190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871512524000190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T23:43:38Z","timestamp":1762559018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871512524000190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443344831"],"references-count":94,"URL":"https:\/\/doi.org\/10.1016\/bs.podrm.2024.10.003","relation":{},"ISSN":["1871-5125"],"issn-type":[{"value":"1871-5125","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}